Visit us at EHA

Oncopeptides presented clinical results from an ongoing Phase I/II study in patients with relapsed and relapsed refractory multiple myeloma in combination with dexamethasone at the European Hematology Association meeting in Vienna.

Upcoming events

Silent Period

-

FDA - Oncologic Drugs Advisory Committee (ODAC) Meeting

The US Food and Drug Administration, FDA, has announced a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (ODAC), on October 28, 2021 concerning Oncopeptides’ product Pepaxto. The information is in line with the FDA safety alert on July 28, where the FDA stated that a public meeting may be hold to discuss the safety findings from the OCEAN study.

Interim Report Q3 2021

08:00 CET

Silent Period

-

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-